Scheme for nonablative hematopoietic transplantation for hematologic malignancy.
Recipients (R) receive a nonmyeloablative preparative regimen designed to achieve engraftment of an allogeneic hematopoietic cell transplant (HSCT). A short course immunosuppressive treatment is given to prevent GVHD. Initially mixed chimerism is present with coexistence of donor (D) cells with recipient-derived normal (R) and leukemia/lymphoma (RL) cells. Recipient and donor patterns of restriction fragment length polymorphisms are shown. Donor-derived T-cells act to eradicate residual recipient-derived normal and malignant hematopoietic cells leading to complete chimerism and remission. Donor lymphocyte infusions (DLI) may be administered to enhance graft-versus-malignancy effects.
